These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

379 related items for PubMed ID: 17692530

  • 1. Pathophysiology and types of dyslipidemia in PCOS.
    Diamanti-Kandarakis E, Papavassiliou AG, Kandarakis SA, Chrousos GP.
    Trends Endocrinol Metab; 2007 Sep; 18(7):280-5. PubMed ID: 17692530
    [Abstract] [Full Text] [Related]

  • 2. Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights.
    Westerveld HE, Hoogendoorn M, de Jong AW, Goverde AJ, Fauser BC, Dallinga-Thie GM.
    Pharmacol Ther; 2008 Sep; 119(3):223-41. PubMed ID: 18602948
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Metabolism of triglyceride-rich lipoproteins and lipid transfer to high-density lipoprotein in young obese and normal-weight patients with polycystic ovary syndrome.
    Rocha MP, Maranhão RC, Seydell TM, Barcellos CR, Baracat EC, Hayashida SA, Bydlowski SP, Marcondes JA.
    Fertil Steril; 2010 Apr; 93(6):1948-56. PubMed ID: 19765700
    [Abstract] [Full Text] [Related]

  • 5. Dyslipidemia in women with polycystic ovary syndrome: incidence, pattern and predictors.
    Rocha MP, Marcondes JA, Barcellos CR, Hayashida SA, Curi DD, da Fonseca ÂM, Bagnoli VR, Baracat EC.
    Gynecol Endocrinol; 2011 Oct; 27(10):814-9. PubMed ID: 20807166
    [Abstract] [Full Text] [Related]

  • 6. Obesity and the polycystic ovary syndrome.
    Martínez-Bermejo E, Luque-Ramírez M, Escobar-Morreale HF.
    Minerva Endocrinol; 2007 Sep; 32(3):129-40. PubMed ID: 17912153
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. LDL species heterogeneity in the atherogenic dyslipidemia of polycystic ovary syndrome.
    Doi SA, Abbas JM, Parkinson L, Chakraborty J, Akanji AO.
    Am J Clin Pathol; 2008 May; 129(5):802-10. PubMed ID: 18426742
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Long-term consequences of polycystic ovary syndrome on cardiovascular risk.
    Rizzo M, Berneis K, Spinas G, Rini GB, Carmina E.
    Fertil Steril; 2009 Apr; 91(4 Suppl):1563-7. PubMed ID: 18976752
    [Abstract] [Full Text] [Related]

  • 15. Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome.
    Berneis K, Rizzo M, Hersberger M, Rini GB, Di Fede G, Pepe I, Spinas GA, Carmina E.
    Int J Clin Pract; 2009 Jan; 63(1):56-62. PubMed ID: 19125993
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome.
    Fenkci SM, Fenkci V, Oztekin O, Rota S, Karagenc N.
    Hum Reprod; 2008 Jul; 23(7):1602-6. PubMed ID: 18378560
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.